Last week, companies like Sunesis Pharmaceuticals, Inc (SNSS) and Chimerix, Inc (CMRX) were in the news due to pipeline updates. While Sunesis’ shares slumped on disappointing data, Chimerix made news related to the Ebola virus. Meanwhile, Regeneron’s (REGN) Eylea continues to gain approval for new indications. Sunesis’ shares tanked 78% on news that a pivotal phase III study being conducted on Qinprezo (vosaroxin) and cytarabine … Continue reading Biotech Stock News: A Look At All the Biotech Stocks For the Past Week

Last week, Incyte Corporation (INCY) received a milestone payment of $60 million from Novartis (NVS) pertaining to the reimbursement of Jakavi in Europe. The drug has been approved by the European Commission to treat adults suffering from primary myelofibrosis (MF), post-polycythemia vera MF or post-essential thrombocythemia MF. It is a common practice of small pharma companies to enter into agreements with larger pharma companies for … Continue reading Biotech Stock Incyte Receives $60M Milestone Payment

Good news flowed in at Regeneron Pharmaceuticals (REGN) when the FDA cleared the company’s highly successful injectable eye drug for macular edema following retinal vein occlusion (RVO), a common retinal vascular disorder. Approval for the broad RVO indication includes sub-indications like, macular edema following branch retinal vein occlusion (BRVO) and macular edema following central retinal vein occlusion (CRVO). We remind investors that Eylea is already … Continue reading Biotech Stock News: Regeneron’s Eylea Gets An Important Approval From FDA